Ultra Performance Liquid Chromatography Tandem Mass Spectrometric Method Development and Validation for Determination of Neratinib in Human Plasma
This study was designed to develop and validate a UPLC-MS/MS method for quantification of neratinib in human plasmsa. Neratinib is an irreversible tyrosine kinase inhibitor against the pan-ErbB (ErbB-1, -2, -4) receptor. UPLC-MS/MS is an excellent analytical methodology for rapid biomedical analysis, decreasing the time for analysis and maintaining good efficiency. Crizotinib was used as internal standard (IS). Samples where extracted by plasma protein precipitation (PPT) procedure with acetonitrile and methanol and analysis was performed on a C18Acquity UPLCBEHTM column. The ion transitions where recorded in positive ion multiple reaction monitoring mode m/z 557.51®112.17 for neratinib and m/z 450.0®260.0 for IS. The mobile phase used was methanol:water: formic acid (70:30:0.1 %, v/v/v) with a flow rate of 0.3mL min–1. The linearity of the assay was found to be 4–500 ngmL–1 for neratinib in human plasma with lower limit of quatification of 4 ngmL–1. The intra- and inter-assay precision relative standard deviations did not exceed 10.99 and mean extraction recovery was found to be 69.12 ± 3.58.
KEYWORDS Neratinib, UPLC, LC-MS/MS, pharmacokinetic study, human plasma.
Copyright for articles published in this journal is retained by the journal.
SAJChem applies the Creative Commons Attribution (CC BY) license to manuscripts we publish. This license was developed to facilitate open access – namely, free immediate access to, and unrestricted reuse of, original works of all types. Under this license, authors agree to make articles legally available for reuse, without permission or fees, for virtually any purpose. Anyone may copy, distribute or reuse these articles, as long as the author and original source are properly cited.